Journal of clinical pathology · 2010
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gazzola Anna, Sista Maria Teresa, Agostinelli Claudio, Righi Simona, Sapienza Maria Rosaria, Mannu Claudia, Rossi Maura, Bacci Francesco, Sabattini Elena, Went Philip, Zinzani Pier Luigi, Pileri Stefano A, Piccaluga Pier Paolo
Аннотация
AIMS: Peripheral T cell lymphoma not otherwise specified (PTCL/NOS) is the commonest PTCL subtype. Recently, proliferation pathways have been found to be commonly altered in PTCL/NOS. CDKN1B/p27, a critical regulator of cell cycle and proliferation, has been suggested to be involved in T cell lymphomagenesis. This study aimed to evaluate the possible occurrence of CDKN1B/p27 aberrations in PTCL/NOS.
METHODS: CDKN1B/p27 expression at RNA and protein level by DNA and tissue microarrays, in 28 and 98 cases, respectively, was studied. Additionally, direct sequencing of CDKN1B in 81 PTCL/NOS was performed.
RESULTS: CDKN1B mRNA was similarly expressed in PTCL/NOS and normal T lymphocytes. In addition, structural abnormalities were not found; these included mutations and deletions in any exons, exon-intron junctions or regulatory regions. Furthermore, physiological expression of p27 in neoplastic cells was demonstrated by immunohistochemistry; this was mutually exclusive with Ki-67, as expected when the system is intact. Consistently, the expression of other molecules that are functionally related to CDKN1B/p27 in controlling cell cycle (including CCNE1) did not appear to be affected at either the mRNA or protein level. Finally, it was found that p27 expression was not significantly related with overall survival.
CONCLUSION: CDKN1B/p27 aberrations seem to be uncommon in PTCL/NOS pathogenesis.
METHODS: CDKN1B/p27 expression at RNA and protein level by DNA and tissue microarrays, in 28 and 98 cases, respectively, was studied. Additionally, direct sequencing of CDKN1B in 81 PTCL/NOS was performed.
RESULTS: CDKN1B mRNA was similarly expressed in PTCL/NOS and normal T lymphocytes. In addition, structural abnormalities were not found; these included mutations and deletions in any exons, exon-intron junctions or regulatory regions. Furthermore, physiological expression of p27 in neoplastic cells was demonstrated by immunohistochemistry; this was mutually exclusive with Ki-67, as expected when the system is intact. Consistently, the expression of other molecules that are functionally related to CDKN1B/p27 in controlling cell cycle (including CCNE1) did not appear to be affected at either the mRNA or protein level. Finally, it was found that p27 expression was not significantly related with overall survival.
CONCLUSION: CDKN1B/p27 aberrations seem to be uncommon in PTCL/NOS pathogenesis.
Предметные рубрики MeSH
Cyclin-Dependent Kinase Inhibitor p27Gene ExpressionGene Expression ProfilingGenes, cdcHumansIntracellular Signaling Peptides and ProteinsLymphoma, T-Cell, PeripheralNeoplasm ProteinsOligonucleotide Array Sequence AnalysisPolymorphism, Single NucleotidePrognosisRNA, MessengerRNA, NeoplasmSurvival AnalysisT-Lymphocyte Subsets